Lexicon Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Lexicon completed enrollment in the Phase 3 SONATA-HCM study, with 542 patients enrolled: 440 classified as non-obstructive and 102 as obstructive at baseline.
- The SONATA-HCM population had a mean baseline KCCQ score of 59, and top-line results are expected in the first quarter of 2027.
- Lexicon reported STENO-1 DKA rates of approximately 1 event per 100 patient-years of sotagliflozin exposure, comparable to the trial’s standard of care group and historic rates in Denmark among people with type 1 diabetes.
- As of the end of August 2026, STENO-1 included 496 patients randomized to SODA and 708 receiving standard of care.
- The IN TANDEM program demonstrated an HbA1c reduction of about 0.4 percentage points, roughly 3 hours per day of additional time in range, fewer hypoglycemic events, reduced body weight, and lowered blood pressure.
- Viatris obtained sotagliflozin regulatory approvals in the United Arab Emirates and Bahrain and submitted applications in more than a dozen additional countries, including Saudi Arabia, Canada, and Australia.
- Lexicon received its 3rd $10 million milestone payment of the year from Novo Nordisk for LX9851 after a Phase 1 development milestone.
- In a preclinical study, 10 mg/kg of pilavapadin reduced body weight by 14% after 28 days; combined with semaglutide, it produced a 31% reduction, compared with 25% for semaglutide alone.
- Third-quarter 2026 total revenues were $11.3 million, compared with $14.2 million in the corresponding period in 2025; 2026 revenue included $10 million in Novo Nordisk milestone revenue and Empepha net sales of $1.2 million.
- Third-quarter 2026 research and development expenses were $16.2 million, compared with $18.8 million in the corresponding period of 2025, while selling, general, and administrative expenses were $9.5 million, compared with $7.6 million.
- Third-quarter 2026 net loss was $14.0 million, or $0.03 per share, compared with a net loss of $12.8 million, or $0.04 per share, in the corresponding period in 2025.
- As of September 30th, 2026, Lexicon had $183.2 million in cash, cash equivalents, and short-term investments, compared with $125.2 million of cash, cash equivalents, short-term investments, and restricted cash as of December 31st, 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the Lexicon Pharmaceuticals Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, November 5th, 2026. I will now turn the call over to Lisa DeFrancesco, SVP Investor Relations and Corporate Communications for Lexicon. Please go ahead, Lisa. Thank you, operator.
Good morning, and welcome to our Third Quarter 2026 Earnings Call. Joining me today are Dr. Mike Exton, Lexicon's Chief Executive Officer and Director, Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer, and Scott Coiante, Senior Vice President and Chief Financial Officer. This morning, Lexicon issued a press release announcing our financial results for the third quarter of 2026, which is available on our website at www.lexpharma.com and through our SEC filings. A webcast of this call along with a slide presentation is also available on our website. During this call, we will review the information provided in the release, provide a corporate update, and use the remainder of the time to answer your questions.
Before we begin, let me remind you that we will be making forward-looking statements, including statements relating to the safety, efficacy, clinical development, regulatory status, and therapeutic and commercial potential of sotagliflozin, pilavapadin, LX9851, and our other drug programs, as well as our business generally. This call may contain forward-looking statements relating to our growth and future operating results, discovery and development of our drug candidates, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. Various risks may cause our actual results to differ materially from those expressed or implied in such forward-looking statements, and we refer you to our most recent annual report on Form 10-K and other SEC filings for detailed information describing such risks. I would now like to turn the call over to Mike Exton.
Mike? Thank you, Lisa. Good day, everyone, and thanks for joining us.
As we approach the end of 2026, a year of tremendous focus and strategic evolution for Lexicon, I want to highlight the significant progress we've made across the business. First and foremost, in HCM, we completed patient enrollment in our phase III SONATA-HCM study. The baseline characteristics reflect the broad spectrum of patients being treated for HCM today, which we believe positions the study to evaluate SOTA across both non-obstructive HCM, where significant unmet need remains, and obstructive HCM, where many patients continue to experience symptoms despite available treatment options. Importantly, the baseline KCCQ score of 59 reflects a highly symptomatic patient population with substantial room for symptomatic improvement. We're very pleased with the overall enrollment profile of SONATA-HCM and look forward to reporting top-line results in the first quarter of 2027.
Now, moving to ZYNQUISTA, we continue to make strong progress towards the resubmission of our NDA in type 1 diabetes, supported by new prospective safety data from the investigator-initiated STENO1 study. We are extremely pleased with the STENO1 safety data, with rates of DKA that were low and comparable to standard of care, as well as the background rate among T1D patients in Denmark. It's worth remembering why this matters. Insulin remains the only glucose-lowering therapy for people with type 1 diabetes, and even with today's pumps and sensors, only about one in five adults reaches the A1C goal of 7%. While much of our recent focus has understandably been on providing the additional safety data requested by the FDA, we don't want to lose sight of the strong efficacy results demonstrated in our phase III inTandem program.
Those results are equally important to evaluating the overall profile of ZYNQUISTA. Taken together, we believe the inTandem efficacy results and the new STENO1 safety data provide a compelling benefit-risk profile for ZYNQUISTA and a strong foundation for our NDA resubmission. We are now preparing that resubmission. Because STENO1 is an investigator-initiated study and was not designed for regulatory purposes, significant work has been required to analyze, format, and prepare the data for submission and review. What remains is bringing this academic dataset up to an agreed-upon regulatory submission standards. We are completing that work in parallel with ongoing discussions with FDA, with the goal of submitting the highest quality package possible and maximizing the probability of a successful review. While this process is taking longer than we originally anticipated, we expect to complete the resubmission in the first quarter of 2027.
We've been unwavering in our commitment to people living with type 1 diabetes and to making sotagliflozin available as a new treatment option. I'm incredibly proud of the work our team has done to get us to this point and grateful to the STENO1 investigators for their collaboration in helping us pursue an innovative regulatory path forward. Now, in heart failure, our licensee, Viatris, continues to expand the global regulatory footprint for sotagliflozin, with regulatory submissions across a growing number of markets outside the U.S. and Europe. To date, Viatris has obtained regulatory approvals in the United Arab Emirates and Bahrain and submitted applications in more than a dozen additional countries, including Saudi Arabia, Canada, and Australia. Turning to LX9851, our first-in-class ACSL5 inhibitor for obesity, the phase I study being conducted by our licensee, Novo Nordisk, is progressing nicely.
During the third quarter, we received our third $10 million milestone payment of the year from Novo, with the potential to receive additional milestone payments as the program advances. We're very pleased with the progress of this promising compound and excited to see Novo continue to move the program forward. Finally, turning to pilavapadin, our conviction in the potential of this agent and its novel AAK1 inhibition mechanism continues to grow. Last quarter, I mentioned that we had exciting work underway exploring its potential in additional high-value indications, and today, I'm pleased to share some of that work, particularly in obesity and weight management. In preclinical studies, pilavapadin has produced significant reductions in body weight, both as a monotherapy and in combination with semaglutide.
While this work remains early, we are encouraged by what we've seen and believe it points to an intriguing new opportunity for this program. We look forward to sharing more on this and additional preclinical programs with pilavapadin. Lastly, and importantly, we've remained steadfast in our commitment to operational excellence and disciplined investment as we advance our programs and prepare for the opportunities ahead. To that end, we recently appointed Rachel Martens as Chief Commercial Officer and added new leaders in marketing and market access to advance our pre-commercial planning in HCM and T1D. I'm extremely pleased with the caliber of talent that we have and continue to attract at Lexicon, which I believe speaks to the strength of our programs and the opportunities ahead of us.
Now, before I turn the call over to Craig, I'd like to return to HCM and spend a few minutes on why we believe this represents such a compelling opportunity for Lexicon and why sotagliflozin may be uniquely positioned to address the significant unmet need across the disease. HCM is a genetic disease characterized by adverse cardiac remodeling, including myocardial hypertrophy, diastolic dysfunction, and fibrosis. Importantly, this underlying biology is the fundamental pathology across both non-obstructive and obstructive HCM. While today much of the innovation in HCM is centered on cardiac myosin inhibitors, which target the contraction mechanism of the heart, sotagliflozin takes a fundamentally different approach. Through its dual SGLT1 and SGLT2 inhibition, we believe sotagliflozin may influence the metabolic and other biological processes that contribute to diastolic dysfunction in HCM.
That distinction's important because the underlying abnormalities in cardiac structure, function, and metabolism extend across both forms of HCM, and we believe this gives SOTA the potential to deliver meaningful benefits in both obstructive and non-obstructive disease, something SONATA-HCM is specifically designed to evaluate. The HCM market is a large and rapidly growing opportunity for a novel agent like SOTA. Awareness and treatment of HCM is accelerating in the U.S. and around the world, but patients continue to experience significant symptom burden that impacts their life. Today in the U.S., more than 800,000 patients have been diagnosed with either obstructive or non-obstructive disease, but there are many more remaining undiagnosed currently. In nHCM in particular, a treatment gap remains, with no disease-specific therapies currently approved despite a patient population growing quickly with rising levels of obesity and diabetes.
There's strong support for an option that is simple, safe, and easy to use for the busy and growing cardiology practices. We believe sotagliflozin's once-daily oral profile, together with its differentiated mechanism and potential applicability across both obstructive and non-obstructive HCM, could provide an attractive option for physicians and patients. With that, Craig Granowitz, our Chief Medical Officer, will provide additional color on our pipeline.
Craig? Thank you, Mike, and good morning, everyone.
As Mike mentioned, SONATA-HCM is the ongoing phase III study for patients with symptomatic HCM, the top-line results of which are expected in the first quarter of next year. SONATA-HCM was designed to evaluate SOTA in a broad HCM population reflective of real-world clinical practice. With the baseline characteristics of the study now available, we are very pleased that the final study population met that objective. Importantly, the demographic and clinical characteristics of both the non-obstructive and obstructive HCM cohorts are generally consistent with those reported in previous clinical studies of other agents in those respective patient populations. The overall study population had a mean baseline KCCQ score of 59. The primary efficacy endpoint of the pivotal study is improvement in symptoms compared to placebo as measured by the change in baseline KCCQ at week 26.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
